PMV Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PMVP research report →
Range $5 – $5
Price Chart
About the company
PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state.
- CEO
- David H. Mack
- IPO
- 2020
- Employees
- 54
- HQ
- Princeton, NJ, US
Get TickerSpark's AI analysis on PMVP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $69.33M
- P/E
- -0.92
- PEG
- -0.09
- P/S
- 0.00
- P/B
- 0.97
- EV/EBITDA
- -0.75
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -78.11%
- ROIC
- -111.08%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-86,206,000
- Net Income
- $-77,742,000-32.4%
- EPS
- $-1.48-30.0%
- OCF Growth
- -43.5%
- FCF Growth
- -41.7%
- 52W High
- $1.88
- 52W Low
- $1.02
- 50D MA
- $1.21
- 200D MA
- $1.27
- Beta
- 1.35
- RSI (14)
- 58
- Avg Volume
- 309.25K
No earnings-call transcripts are available for PMVP yet.
- Free Float
- 91.7%
- Shares Outstanding
- 53.33M
- Float Shares
- 48.90M
of shares held by institutions
63 13F filers
Buy/sell ratio 6.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 2.17M | ▲ 7.28K |
| Two Sigma Advisers, LP | 874.10K | ▲ 456.20K |
| Cubist Systematic Strategies, LLC | 43.87K | ▲ 43.87K |
Held by 26 ETFs
Biggest fund positions in PMVP by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 4, 26 | Stelzer Laurie | other | 42,000 |
| Jun 4, 26 | LEVINE ARNOLD J | other | 42,000 |
| Jun 4, 26 | Gallagher Carol Giltner | other | 42,000 |
| Jun 4, 26 | Gallagher Carol Giltner | other | 42,000 |
| Jun 4, 26 | Gallagher Carol Giltner | other | 42,000 |
| Jun 4, 26 | FLOWERS KIRSTEN | other | 42,000 |
| Jun 4, 26 | BAUM CHARLES M | other | 42,000 |
| Mar 5, 26 | Carulli Michael | other | 240,000 |
| Mar 5, 26 | Ticktin Robert | other | 319,270 |
| Mar 5, 26 | Jalota Deepika | other | 303,310 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PMVP coverage
Recent articles, reports, and earnings notes.
No research on PMVP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PMVP report →PMV Pharmaceuticals (PMVP) Upgraded to Buy: What Does It Mean for the Stock?
zacks.com · Aug 19
PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights
globenewswire.com · Aug 14
PMV Pharmaceuticals (PMVP) Upgraded to Buy: Here's Why
zacks.com · Jun 24
PMV Pharmaceuticals (PMVP) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
zacks.com · Jun 10
PMV Pharmaceuticals Announces Board Chair Transition
globenewswire.com · Apr 22
PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights
globenewswire.com · Mar 6
PMV Pharmaceuticals (NASDAQ:PMVP) versus Aurinia Pharmaceuticals (NASDAQ:AUPH) Financial Comparison
defenseworld.net · Nov 23
PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
globenewswire.com · Oct 24
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.